Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of nex... Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others. Show more
CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced an update on its progress in catalyzing the Company’s next stage of growth. The...
CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced that Regina Graul, Ph.D., has been promoted to Chief Executive Officer...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0702 | -2.02305475504 | 3.47 | 3.79 | 2.8 | 241277 | 3.07120818 | CS |
4 | 1.9798 | 139.422535211 | 1.42 | 9.4699 | 1.27 | 9053661 | 5.52352959 | CS |
12 | 0.7098 | 26.3866171004 | 2.69 | 9.4699 | 1.27 | 3256077 | 5.30245818 | CS |
26 | 1.2098 | 55.2420091324 | 2.19 | 9.4699 | 1.27 | 1529635 | 5.29728817 | CS |
52 | -1.4802 | -30.3319672131 | 4.88 | 9.4699 | 1.27 | 778411 | 5.29351876 | CS |
156 | -32.4002 | -90.5033519553 | 35.8 | 37.8 | 1.27 | 362344 | 7.87088367 | CS |
260 | -40.6002 | -92.2731818182 | 44 | 179.2 | 1.27 | 452401 | 42.35496776 | CS |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales